Merck Introduces Aptegra CHO genetic stability assay for accelerated biosafety testing

Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind.

Risk Adjusted Net Present Value: What is the current valuation of AbbVie’s Navitoclax dihydrochloride

The revenue for Navitoclax dihydrochloride is expected to reach an annual total of $315 mn by 2034 in the US based off GlobalDatas Expiry Model.

September 8, 2024

New tool revolutionizes primer design for infectious disease detection

Researchers from the Zhang Liye Laboratory have developed a groundbreaking tool that revolutionizes the way researchers design primers for detecting pathogens.

March 4, 2025

Prostate cancer incidence rises in California following screening guideline change

Following a change in screening guidelines, the incidence went up across the state, even more than it has nationally.

February 3, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.